Good day, everyone, and welcome to the Doximity Q4 2025 earnings call. At this time, I will hand the call over to Perry Gold, Head of IR. Please go ahead, sir.
Thank you, Operator. Hello and welcome to Doximity's Fiscal 2025 Fourth Quarter earnings call. With me on the call today are Jeff Tangney, Co-founder and CEO of Doximity; Dr. Nate Gross, Co-founder and CSO; and Anna Bryson, CFO. A complete disclosure of our results can be found in a press release issued earlier today, as well as in our related Form 8K, along with a copy of our prepared remarks, all available on our website at investors.doximity.com. As a reminder, today's call is being recorded, and a replay will be available on our website. As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations, and assumptions, and are subject to various risks and uncertainties. Actual results may differ materially, and we disclaim any obligation to update any forward-looking statements or outlook.
Please refer to the risk factors in our annual report on Form 10K, any subsequent Form 10Qs, and our other reports and filings with the SEC that may be filed from time to time, including our upcoming filing on Form 10K. Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, May 15th, 2025. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call unless it is also done through a public disclosure, such as a press release, or through the filing of a Form 8K. Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release.
Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one-time in nature, and we may or may not provide updates on those metrics in the future. I would now like to turn the call over to our CEO and Co-founder, Jeff Tangney. Jeff?
Thanks, Perry, and thank you, everyone, for joining our Fourth Quarter earnings call. We have three topics today: our financials, network growth, and client summit recap. First, our top line. We delivered $138 million in revenue for the Fourth Quarter of our Fiscal 2025, 4% above the high end of our guidance range. For our full Fiscal Year ended March 31st, we had $570 million in revenue and grew 20% year on year. Of note, our top 20 clients, who know and measure us best, once again grew the fastest at 23% in Fiscal 2025. Our bottom line was also strong in Q4, with an adjusted EBITDA margin of 50%, or $70 million, which was 10% above the high end of our guidance. Our free cash flow was stronger still at $97 million, up 56% year on year.
For the full Fiscal Year, our adjusted EBITDA grew 36% to $314 million. Our adjusted EBITDA margin was 55% for the year, up from 48% the prior year. We generated free cash flow of $267 million, an increase of 50% year on year. Okay, turning now to our network growth and engagement. Our unique active users on a Quarterly, monthly, weekly, and daily basis all hit fresh highs in Q4. This growth was again led by our newsfeed, which is both our most used and most monetized product. Our unique newsfeed users hit record highs last Quarter, while our articles read or tapped were up more than 30% year on year. Our workflow tools also hit fresh highs in Q4, with over 620,000 unique active prescribers. As a reminder, our workflow tools include our telehealth, fax, scheduling, and AI tools.
Our AI tools grew the fastest again last Quarter, up more than 5X year on year. In short, as the practice of medicine grows both more mobile and more AI-powered, we're proud to be leading the way. Okay, turning now to our recent physician and pharma client summits. In March, we hosted our 13th annual Physician Tech Summit in San Francisco. It was great to roll up our sleeves for two days alongside 150 of our nation's most tech-savvy doctors. For the third year in a row, our Doximity GPT products took center stage. Physicians love our specialty-specific AI tools and HIPAA-secure environment, and we're learning a lot from their real-world use. One popular new feature is our ability to upload and securely analyze documents.
Per a recent JAMIA study, a fifth of patients nowadays have medical records that are lengthier than Moby Dick, so for a specialist treating a new patient, it can literally take hours of reading to fully come up to speed. With Doximity GPT, they can just upload the patient's file, and our AI can chart the patient's lab values over time, summarize key clinical findings, or search for complex diagnostic clues. It is a long-overdue cure for what physicians affectionately call "note bloat." In a short couple of years, we have seen AI tools like this truly change the mood in medicine, from AI leery to AI cheery. For the first time in over a decade, there is genuine hope that physician burnout and information overload can actually be eased with technology. We are incredibly proud and motivated to help, crafting AI tools that just work for busy clinicians.
This is our mission and our roots as a team. Following our Physician Summit last month, I have personally shifted my focus from our client portal to our clinical AI products. Speaking of our client portal, the rollout's going very well. The majority of our pharma clients now have access, and they love tracking their day-to-day results and ROI. These daily portal insights are also fueling client interest in how our new AI-powered integrated offerings can help them automate their programs. This AI orchestration was a key theme at our annual pharma client summit in New York last week, where we were joined by over 40 marketing leaders from the world's largest pharmaceutical companies. Their top request was to use our AI to optimize their programs at a more strategic level.